英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
schanke查看　schanke　在百度字典中的解释百度英翻中〔查看〕
schanke查看　schanke　在Google字典中的解释Google英翻中〔查看〕
schanke查看　schanke　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
    With our recently reported platform validation we are entering a new chapter in CureVac’s development, which marks a natural transition for me CureVac is stronger than ever as I hand over to Alexander Zehnder His expertise will add a lot to shape the future success of CureVac ”
  • A New Chapter Begins Today marks a truly exciting and . . . - LinkedIn
    Alexander Zehnder, MD, MBA Zehnder, CEO of CureVac: “To me, this transaction is more than a business decision, it represents a shared commitment to leverage the full potential of mRNA as a
  • CureVac — Wikipédia
    Historique L’entreprise est créée en 2000 par Ingmar Hoerr (CEO), Steve Pascolo (Chief Scientific Officer) et Florian von der Mulbe En octobre 2013, CureVac lance une collaboration avec Janssen Pharmaceuticals Inc, une filiale de Johnson Johnson, pour le développement de nouveaux vaccins contre la grippe 5
  • Alexander Zehnder - CEO at CureVac | The Org
    Alexander Zehnder, MD, MBA, currently serves as the Chief Executive Officer of CureVac since April 2023
  • CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
    CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes
  • CureVac N. V. . (1 10 23). Press Release: CureVac Appoints Alexander . . .
    CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes
  • CureVac N. V. . (1 17 24). Press Release: CureVac CEO Alexander Zehnder . . .
    CureVac N V (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that its Chief Executive Officer, Alexander Zehnder, recently purchased 50,000 common shares of CureVac stock
  • CureVac appoints Alexander Zehnder as CEO - TipRanks. com
    CureVac N V announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr Franz Haas will step down as CEO, effective March 31, 2023
  • CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
    mous potential of our proprietary mRNA technology,” said Dr Alexander Zehnder, Chief Executive Officer of CureVac “We are b ilding a strong clinical pipeline for prophylactic vaccines and are increasing our footprint in cancer immunotherapy My purchase shows my continued commitment to the company and confidence in the value of our
  • Who is the CEO of CureVac (CVAC)? - financecharts. com
    CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA) The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees





中文字典-英文字典  2005-2009